|View printer-friendly version|
Spring Bank Pharmaceuticals Doses the First Patient in the ACHIEVE Global Phase 2 Program of SB 9200 in Hepatitis B (HBV)
“The Phase 2a study is designed to enable the rapid identification of the optimal dose of SB 9200 as monotherapy by evaluating the reduction in HBV DNA and HBsAg at 12 weeks,” said
This Phase 2a study has an adaptive trial design that will enroll 80 chronically-infected HBV patients between 18 and 70 years of age who will be assigned to one of four dosing cohorts, 25 mg, 50 mg, 100 mg or 200 mg of SB 9200, or placebo, once daily for 12 weeks. All subjects will then receive tenofovir 300 mg once daily for an additional 12 weeks of treatment. The Phase 2b portion of the ACHIEVE program is planned to examine the concomitant use of SB 9200 and tenofovir in 200 HBV patients.
“We are excited to begin our Phase 2 program and further our understanding of the therapeutic efficacy and safety of SB 9200,” said Radhakrishnan (
“The initiation of ACHIEVE represents an important step forward for our SB 9200 development program, as it is the first human trial to evaluate SB 9200 in chronic Hepatitis B patients,” said
Viread is a registered trademark of
Any statements in this press release about Spring Bank’s future expectations, plans and prospects, including statements about Spring Bank’s financial prospects, future operations and sufficiency of funds for future operations, clinical development of Spring Bank’s product candidates, expectations regarding future clinical trials and future expectations and plans and prospects for